About Fred

Fred Dorey is a special counsel in Cooley business department with more than 25 years experience counseling over 100 emerging growth private companies at all stages of development from startup discussions and incorporation through licensing, financing, corporate partnering and major collaboration transactions. Fred is active in Cooley’s Life Sciences, Clean Energy and Agricultural technology groups, representing a wide range of companies in those fields and related technologies. He also has extensive experience negotiating university licenses, sponsored research and intellectual property agreements.

View full bio

Experience

  • Decibel Bio Closes $12 Million Financing Round

    • Decibel Bio Closes $12 Million Financing Round

    March 5, 2025

    Cooley advised Decibel Bio, a plant biotechnology company building the world’s first crop epigenetic platform, on its $12 million financing round. The funding will be used to advance Decibel’s proprietary platform for both reading and writing the plant epigenome to create crop varieties with higher yield, efficiency and resilience to a changing environment.

    Related contacts

    Frederick Dorey
    Special Counsel, Palo Alto
    Katie Weeks
    Associate, Palo Alto

    Related Practices & Industries

    Agricultural Sciences and Technology

  • Cooley advises Pivot Bio on $430 Million Series D Financing

    • Cooley advises Pivot Bio on $430 Million Series D Financing

    August 27, 2021

    Cooley advised California-based agricultural biotech growth company Pivot Bio on its $430 million Series D funding round. Pivot Bio has raised over $600 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. “We have earned the trust of farmers for our direct-to-grower approach and have proven that our products provide consistent yields and profits for farmers, even in the face of a volatile climate,” said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

    Related contacts

    Frederick Dorey
    Special Counsel, Palo Alto

    Related Practices & Industries

    Emerging Companies
    Venture Capital
    Agricultural Sciences and Technology

  • Cooley advises Inflammatix on $102M Series D Round

    • Cooley advises Inflammatix on $102M Series D Round

    March 24, 2021

    Cooley advised Inflammatix, a pioneering molecular diagnostics company, on its $102 million Series D funding round to support the development and commercialization of the company’s novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures. Inflammatix’s diagnostics rapidly read the patient’s immune response to infections across multiple mRNA biomarkers using machine learning algorithms. The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. 

    Related contacts

    Frederick Dorey
    Special Counsel, Palo Alto
    Anita Vasudevan
    Special Counsel, Palo Alto

    Related Practices & Industries

    Life Sciences
    Emerging Companies
    Venture Capital

  • Cooley advises Pivot Bio on $100M Series C Round

    • Cooley advises Pivot Bio on $100M Series C Round

    May 4, 2020

    Cooley advised California-based agricultural biotech growth company Pivot Bio on its $100 million Series C funding round, co-led by repeat investors Breakthrough Energy Ventures and a global investment company. Pivot Bio has raised $186 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. "The strong backing by our Series C investors enables Pivot Bio to redefine the future of fertilizer and provide the world's farmers with a new nitrogen source. Based on remarkable demand, we expect to ramp up from our large current footprint to millions of additional acres in the next growing season." said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

    Related contacts

    Frederick Dorey
    Special Counsel, Palo Alto
    John Sellers
    Senior Counsel, Palo Alto
    Emily Iannarelli
    Associate, Palo Alto
    Lauren Creel
    Partner, Palo Alto
    Dr. Chris Holly
    Partner, Washington, DC
    Judd Lauter
    Special Counsel, San Francisco
    Karen Gustavson
    Associate, Seattle

Admissions and credentials

  • California
  • District of Columbia

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.